Achillion Pharmaceuticals, Inc. (ACHN) Trading Up 17.5%
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was up 17.5% during trading on Friday . The company traded as high as $3.70 and last traded at $3.56. Approximately 14,869,300 shares changed hands during mid-day trading, an increase of 799% from the average daily volume of 1,653,462 shares. The stock had previously closed at $3.03.
A number of equities research analysts recently commented on ACHN shares. Ladenburg Thalmann Financial Services dropped their target price on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research report on Tuesday, September 12th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 14th. Chardan Capital dropped their target price on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 9th. Robert W. Baird reiterated a “neutral” rating and issued a $4.00 target price (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research report on Tuesday, September 12th. Finally, BidaskClub lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $5.29.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period in the previous year, the business posted ($0.15) earnings per share. analysts predict that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in ACHN. RTW Investments LP lifted its position in shares of Achillion Pharmaceuticals by 392.9% during the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock valued at $35,201,000 after buying an additional 6,249,312 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Achillion Pharmaceuticals during the 2nd quarter valued at approximately $20,778,000. Sarissa Capital Management LP purchased a new position in shares of Achillion Pharmaceuticals during the 3rd quarter valued at approximately $9,594,000. Dimensional Fund Advisors LP lifted its position in shares of Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after buying an additional 1,407,108 shares in the last quarter. Finally, Senzar Asset Management LLC purchased a new position in shares of Achillion Pharmaceuticals during the 2nd quarter valued at approximately $4,966,000. Institutional investors and hedge funds own 74.81% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.